Purpose Venous thromboembolism (VTE) is common; deep venous thrombosis (DVT) and pulmonary embolism (PE) are the most common presentations. VTE may arise from anywhere in the entire venous bed and the diagnosis may be difficult. VTE is a dynamic disease, inflammation is key, and 18 F-Fluorodeoxyglucose positron emission tomography/computer tomography (FDG-PET/CT) has been proposed in the evaluation of VTE to detect thrombi in any anatomic location, to differentiate acute from chronic VTE, and to differentiate bland VTE from tumor thrombosis. The aim of this systematic review was to assess if the potential uses of FDG-PET/CT in VTE are described and documented in the literature and to appraise the literature. Methods PubMed and Embase databases were searched. Duplicates and papers in other languages than English and Scandinavian were removed. Remaining papers were screened by title and abstract. Eligible papers were assessed in full text. Results The master search yielded 3897 hits; 316 papers were eligible for full-text assessment. Ten papers were included: six on diagnostic performance of PET/CT in VTE, and four on the ability of PET/CT to differentiate bland VTE from tumor thrombosis. Three papers were prospective; seven were retrospective. Conclusion The available literature is too sparse to draw firm conclusions; however, FDG-PET/CT may have a role in diagnosing early DVT, but not PE, in discriminating acute from chronic VTE, in demonstrating recurrent VTE, and possibly for screening for occult malignancy.
Introduction
Since the introduction of the term embolus by German pathologist Rudolf Virchow and the subsequent presentation of his etiologic triad (hypercoagulability, hemodynamic changes, endothelial injury/dysfunction) in the middle of the nineteenth century [1] , the clinical characteristics and diagnosis of venous thromboembolism (VTE) have been a subject of debate.
VTE is a common disease with about 1 million reported cases annually in the US and Europe and an estimated annual incidence throughout the Western World of 100-300 per 100,000, increasing with age [2, 3] . VTE is a dynamic disease and inflammation plays a key role: The coagulation cascade is initiated when damaged endothelium summons platelets that cluster at the site of wall damage while embedding red blood cells and fibrin in alternating layers [4] . Adherence of the thrombus to the vessel wall triggers hyperaemic inflammation, and endothelial cells respond to injury by releasing pro-coagulant factors and pro-inflammatory 1 3 cytokines leading to further platelets and white cells being incorporated in the acute thrombus [5] . Deep venous thrombosis (DVT) arises mainly in deep veins of the lower extremities, and proximal thrombus fragments may detach and lodge in the pulmonary vasculature as pulmonary emboli causing a pulmonary embolism (PE).
The diagnosis of VTE is difficult due to unspecific signs and symptoms [6] . Many are routinely missed, since, according to large autopsy studies, 15% of deaths of hospitalized patients are attributable to VTE, while only 30% of these were diagnosed ante mortem [5] . Thus, many deaths are potentially avoidable; relevant and timely treatment may decrease mortality substantially, but carries a risk of dangerous side effects [7] . Most current imaging techniques for the detection of VTE are based on regional and structural imaging of venous thrombi, but are hampered by the fact that the two most common manifestations, DVT and PE, are present in only a fraction of VTE cases, which may arise anywhere in the venous bed. Ultrasound and computed tomography (CT) venography can detect thrombi in the thigh, but not necessarily in the calves. CT angiography (CTA) and ventilation/perfusion scintigraphy (V/Q scan) are well established for detection of PE when performed with state-of-the-art technique, but CT with contrast is contraindicated in approx. one quarter of patients and implies considerable radiation exposure, while ventilation/perfusion scintigraphy cannot assess the venous system [8, 9] .
We previously proposed 18 F-Fluorodeoxyglucose positron emission tomography/computer tomography (FDG-PET/ CT) for the diagnosis of VTE as it may overcome shortcomings of other methods [10] . Thus, PET can potentially detect thrombi in any anatomic location of the body, potentially discriminate between acute (FDG avid) and inactive chronic (non-avid) VTE, as well as potentially differentiate bland thrombus (BT) from tumor thrombus (TT) while automatically screening for occult cancer throughout the body. The aim of this systematic review was to get an impression of which of the many potential uses of FDG-PET/CT in VTE are described and documented in the literature and to appraise the available literature.
Materials and methods

Search strategy
A comprehensive literature search was performed by the first author (SH) and a librarian. We searched PubMed (1946-December 31, 2016) and Embase (1974-December 31, 2016) using the search strings without limits presented in Table 1 . Duplicates and papers in other languages than English and Scandinavian were removed. Remaining papers were screened by title and abstract. Eligible papers were assessed in full text according to predefined inclusion and non-inclusion criteria presented below. Article sorting from master search to final inclusion was performed independently by two authors (SH and ECF). Any discrepancies were reviewed and resolved by consensus. An updated search was performed according to the same procedure covering the period from 1 January 2017 to 1 August 2018. For more details, see Fig. 1 .
Inclusion and non-inclusion criteria
Inclusion criteria were (1) original articles with ≥ 10 human patients in which (2) FDG-PET/CT was used for (3) diagnosis of BT or (4) differentiation between BT and TT. The following types of papers were excluded: animal reports, phantom studies, technical papers, conference papers and proceedings, editorials and commentaries, reviews and meta-analyses, guidelines, book chapters, and papers with insufficient reference standards with respect to the criteria outlined above. The diagnostic test characteristics were analyzed in each article, i.e., sensitivity, specificity, positive and negative predictive values (PPV and NPV), accuracy, and/or semi-quantitative parameters derived from presented results or calculated from available information. To provide an exhaustive overview of all published papers about FDG-PET/CT in VTE imaging, we registered also all case reports or case series with < 10 patients. Papers were quality assessed according to QUADAS-2.
Results
The master search yielded 3897 hits. After removal of duplicates (n = 778), and exclusion of records based on screening of title or abstracts (n = 2,803), a total of 316 papers were eligible for full-text assessment. The ensuing sorting process yielded ten original articles, cf. the flow chart in Fig. 1 and overview in Table 2 ; most papers were excluded as being not relevant, e.g., without PET imaging. Of the included papers, five papers were on the diagnostic performance of PET/CT in DVT (n = 3) or PE (n = 3) [11] [12] [13] [14] [15] , and four were on the ability of PET/CT to differentiate TT from BT [16] [17] [18] [19] . Two papers presented data on changes in FDG uptake over time [12, 20] . Three papers were prospective, and seven were retrospective. Median number of patients in included studies were 15 (range 10-100). The same procedure applied to case reports, and this yielded 40 case reports. A renewed search covering 1 January 2017 to 1 August 2018 using the same procedure as above yielded 99 hits from PubMed and 264 hits from EMBASE. After removal of duplicates (n = 6), and exclusion of records based on screening of title or abstracts (n = 318), a total of 39 papers were eligible for full-text assessment. The ensuing sorting process yielded three additional case reports but no further clinical studies.
Due to the limited number of comparable papers within each subcategory, strict application of QUADAS 2 quality assessment was not considered meaningful. We have, however, included overall tabular results for the four papers on differentiating bland thrombus from tumor thrombus as supplemental data.
Discussion
We performed a comprehensive systematic literature search in conjunction with an information specialist librarian and the entire sorting procedure was performed independently by two different physicians. The result from the master search (3897 titles) was reduced to 10 eligible papers of original research and 43 case reports, which indicates a relatively broad search strategy. For the same reason, the librarian did not recommend a perusal of included papers' reference lists for missed papers as it is generally considered futile if the initial search strategy is sufficiently broad termed. The included papers were divisible into various subcategories that were all in line with well-known controversies in VTE (cf. the following section); i.e., overall diagnosis, differentiation between BT and TT, management of recurrent VTE, and the issues of cancer comorbidity.
PE derives primarily from DVT in pelvic or lower extremity veins, and in most cases (~ 75%), there is evidence of symptomatic or asymptomatic DVT. Some studies have estimated that half of the patients with untreated DVT will progress to PE within 3 months [21] . Clinical probability scores may aid clinicians, but are relatively non-specific; a meta-analysis of 22 studies found 11% of patients with a low probability Wells score positive for DVT, whereas 56% of patients with a high probability Wells score had DVT [22] . Similar results have been found for clinical prediction scores in PE [23] . Today, the diagnoses of DVT and PE are primarily based on compression ultrasound, and V/Q scan or CTA, respectively. In general, compression ultrasound has excellent sensitivity in symptomatic patients with proximal lower extremity DVT, but in other clinical settings, the sensitivity may be as low as 21%. In patients with PE, compression ultrasonography of the proximal leg veins found DVT in 29-58%, whereas autopsy studies have found DVT in > 80% [10] . Similarly, CTA and V/Q scans may have excellent sensitivity and specificity when employed in the proper clinical setting, but CTA may miss peripheral PE and contrast media precludes the use in up to 25% of patients. Whereas, the V/Q scan has a high number of inconclusive results if not performed with state-of-the-art SPECT/CT technique, which is not generally abundant [8] .
More than half of the DVTs occur in calf veins or pelvic veins, where ultrasonography has limited sensitivity and none of the above-mentioned techniques address vessels outside the pulmonary and proximal femoral vasculature. FDG-PET/CT provides whole-body assessment, and a mounting number of case reports demonstrate sightings of venous activity consistent with VTE in venous vasculature throughout the body and in various clinical settings: lower extremity veins [24] [25] [26] [27] [28] , iliac vein [26] , upper extremity veins [29] [30] [31] , superior vena cava [32, 33] , inferior vena cava [34] [35] [36] , portal vein [36, 37] , renal vein [34] , jugular vein [38] , brachiocephalic vein [33, 39] , indwelling catheters [40] [41] [42] , superior sagittal sinus [33, 43] , pulmonary embolism (including supposed microembolism from injection artifacts) [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] , lung infarction [62] [63] [64] , right-heart strain secondary to PE [65] , and inferior mesenteric vein [66] . Flavell et al. [13] retrospectively studied FDG avidity and other findings indicative of PE in patients diagnosed with incidental previously unknown PE by contrast-enhanced CT and found an incidence of 0.32% (59/18,272), 9/59 (15%) in the main pulmonary artery, 15/59 (25%) in lobar arteries, 27/59 (46%) in segmental arteries, and 8/59 (14%) in subsegmental arteries. No independent reference standard was employed. Looking retrospectively for PET-related findings in patients with PE, the authors found a low sensitivity for PE of 22% (13/59) . Nine of 59 demonstrated focal hypermetabolism in the pulmonary arteries related to the location of CT-verified PE (11% in the main pulmonary artery, 22% in lobar arteries, 44% in segmental arteries, and 22% in subsegmental arteries). Three of 59 displayed hypermetabolic infarction, and one had a high SUV in the right ventricle. Maximum SUV and mean SUVmax in PE-positive vessels were 3.2 and 2.2 ± 0.7, respectively [13] .
Diagnosis
Rondina et al. [12] presented the first prospective series in a case-control setup with twelve patients with unprovoked ultrasound-verified DVT and 24 controls without DVT who underwent whole-body FDG-PET/CT. SUVmax of the thrombosed vessel was determined and compared to that of the contralateral non-thrombosed vessel and of normal controls. Mean SUVmax in DVT patients was 2.41 versus 1.1 in contralateral vessel (p = 0.007) and 1.21 in controls (p < 0.001). The area under the receiver operating characteristics (ROC) curve was excellent for SUVmax (0.9773, p < 0.001), and a SUVmax cut-off of 1.645 yielded a sensitivity of 87.5% and a specificity of 100%. Sensitivity increased to 100% and specificity decreased to 87.5% with a threshold of 1.49. The authors also observed a negative correlation between FDG uptake in thrombosed veins and time from onset of DVT symptoms, i.e., a decrease in SUVmax of 0.02/day and registered normalization of FDG uptake 84-91 days after onset of DVT. However, only 12 of 67 eligible patients were included, mean time span from symptom onset to PET/CT was more than one month (range 1-10 weeks), and only two patients underwent serial PET/ CT for assessment of temporal changes [12] .
Hess et al. [14] prospectively examined 15 patients with suspected DVT and/or PE who underwent subsequent FDG-PET/CT less than 24 h after confirmed or rejected diagnosis according to local guidelines. By visual interpretation, DVT/ PE was considered present if focal or linearly increased FDG uptake was observed within the veins/pulmonary vasculature. FDG-PET/CT was able to correctly diagnose or rule out DVT in all patients, but was positive in only two of six PE cases [14] . Based on the same data and reported in an abstract [67] , the same researchers found that the volumetric parameters metabolically active volume (MAV), total lesion glycolysis (TLG), and SUVmax relative ratios were the most robust predictors of DVT, while areas under the ROC curve were 0.96 for MAV (p = 0.005), 0.94 for TLG (p = 0.007), and 0.89 for SUVmax (p = 0.03). For detection of DVT, relative ratio of MAV > 258% showed 84% sensitivity and 100% specificity, and relative ratio of TLG > 283% yielded 84% sensitivity and 100% specificity, while relative ratio of SUVmax > 11% had 84% sensitivity and 87% specificity. Thus, volumetric FDG-PET/CT parameters may be potential biomarkers for detection of DVT.
Le Roux et al. [15] reported about 98 consecutive patients with idiopathic VTE diagnosed by CTA (n = 52), and/ or VQ scan (n = 37), or compression ultrasound (n = 96), who subsequently underwent PET/CT to locate underlying occult cancers. No reference standard for VTE diagnosis was employed. They found exceptionally low sensitivities, but good specificities with PET/CT in both PE (9 and 84%, respectively) and DVT (31 and 88%, respectively). Considering the results of Rondina et al. [12] the most likely explanation for the somewhat peculiar results of Le Roux et al. was normalization of the FDG uptake since the time interval between the VTE diagnosis and PET/CT was up to 1 3 2 months, a finding that was substantiated by a recorded tendency towards higher SUVmax in patients with more recent DVTs [15] .
In conclusion, few studies with few patients have assessed the diagnostic value of FDG-PET/CT in suspected VTE. Findings are generally positive for DVT, but of limited use in PE. For the time being, FDG-PET/CT will hardly replace compression ultrasound for routine assessment of DVT. However, as previously suggested [10] , there may be a role for FDG-PET/CT when looking for VTE in vessels not easily assessed by ultrasound, e.g., iliofemoral vein or veins in very obese patients. Furthermore, PET may better determine the age of a thrombus; this may have therapeutic implications in acute versus chronic VTE or suspected recurrence.
Differentiation between bland and tumor thrombosis
Differentiation between conventional BT and TT is clinically relevant due to a different therapeutic approach, i.e., anticoagulation versus anticancer treatment. Four studies assessed the ability of FDG-PET/CT to differentiate BT from TT.
Davidson et al. [16] evaluated 11 patients retrospectively; eight were included due to increased focal or linear vascular uptake on PET scans and three had suspicious findings on contrast-enhanced CT. Findings were classified as FDG positive (considered to be TT) or FDG negative (considered to be BT) and subsequently compared to concurrent imaging, primarily CT, histopathology was used in only one case. All TT patients received chemotherapy, the two BT patients anticoagulation. Follow-up imaging showed resolution in all cases, and the authors concluded that the appropriate treatment had been administered in all case cases and, thus, considered the differentiation between BT and TT to be 100% accurate.
Sharma et al. [17] retrospectively included 24 patients with known malignancies scanned for staging purposes subsequently found to have FDG-avid thrombosis, i.e., focal or linearly increased vascular uptake. Notably, only intraluminal uptake, and not uptake in the vessel wall, was considered indicative of thrombosis. Reference standard for TT was concurrent imaging (8/14) or histopathology/clinical follow-up (6/14). Reference standard for BT was imaging (4/10) or response to anticoagulation treatment (6/10). SUVs were recorded for primary tumor and thrombi, and there was a correlation between primary tumor SUVmax and TT SUVmax and significant differences between SUVmax of TT and BT. ROC analysis with a cut-off SUVmax of 3.63 yielded sensitivity and specificity for differentiating TT from BT of 71 and 90%, respectively.
Lee et al. [18] retrospectively included 15 patients with 24 sites of VTE according to contrast-enhanced CT. Reference standard was histopathology (n = 3) or imaging follow-up (n = 12); in the latter case, response to antithrombotic therapy was considered indicative of BT, whereas progression was considered to be TT. However, no information on chemotherapy was presented. SUVmax was employed and a significant difference between TT SUVmax and BT SUVmax was found. ROC analysis with a SUVmax cut-off of 2.25 yielded sensitivity and specificity for differentiation between TT and BT of 78 and 100%, respectively. An even better sensitivity (83%) with preserved specificity could be accomplished with a ROC-based SUVmax cut-off of 1.58 for tumor SUVmax/mediastinal SUVmax ratio.
A study by Hu et al. [19] was the most recent of the included papers as well as the largest one; 72 patients with incidental findings of portal vein thrombosis on staging/restaging PET/CT scans were included retrospectively, 47 TT and 25 BT. The diagnoses were confirmed by histopathology (n = 38) or structural imaging and clinical follow-up (n = 34). The authors tested a visual 4-point scale and semiquantitative SUVmax. The former was assessed relatively to the activity in the aorta from 0 (no uptake) to 3 (higher than aorta); 0-2 was considered negative and consistent with BT, whereas 3 was considered positive and specific for TT. Applying these criteria yielded sensitivity, specificity, and accuracy of 92, 64, and 82%, respectively, whereas ROC analysis with an optimal SUVmax cut-off of 3.35 resulted in sensitivity, specificity, and accuracy of 92, 64, and 82%, respectively.
Based on the available literature FDG-PET/CT seems very adept at differentiating BT from TT visually and semiquantitatively, albeit with varying sensitivities (71-100%) and specificities (64-100%). However, there are major caveats. First of all, from the aforementioned it is clear that the fundamental premise that BT is FDG negative and TT is FDG avid is flawed. BT is often highly FDG avid as demonstrated in many case reports and clinical trials. In this light, the lack of systematic histopathologic confirmation of TT is another major drawback as is the overall premise that resolution following either chemotherapy treatment or anticoagulation is indicative of the underlying type of thrombus. This may be true with TT, but it is conceivable that BT in a cancer patient will resolve spontaneously. Thus, the results are interesting, but further studies with stringent methodology are called for to better assess the ability of FDG-PET/ CT to differentiate BT from TT.
Recurrent VTE
The risk of recurrent VTE is substantial, i.e., up to a 40-fold increase compared with that of previously unaffected individuals [68] . In patients with unprovoked DVT, the risk is up to three times higher than in patients with reversible risk factors [69] . Patients suspected of recurrent VTE represent a diagnostic challenge, since only about one in four will actually have a recurrent acute DVT that may trigger active treatment [4] . Also, early recurrence tends to be predisposed to the same leg, probably due to reactivation of the former thrombus, or simply because the initial vessel damage is still present and the risk of recurrence is greater when anticoagulants are discontinued, while there is still residual DVT present on ultrasound imaging [21] . Since morphologic changes may remain present for years, patients with a prior history of VTE represent a challenge as it may be difficult to differentiate new from residual clots [68] . Clinically, DVT can be classified as acute, primarily composed of red blood cells, platelets, and fibrin, and with predominant inflammation. Later, as the DVT becomes subacute, inflammation subsides and thrombus composition changes towards more fibrotic constituents and, finally, the thrombus becomes chronic with increasing recanalization and no inflammation [70] . Thus, FDG-PET/CT has the potential to characterize the thrombus temporally, and aid in the differentiation of new and active clots from residual chronic ones.
This theory was, to some extent, corroborated by the findings in the above-mentioned study by Rondina et al. with its limited number of patients [12] . They found a negative correlation between the metabolic activity of the thrombi and the time from onset of symptoms to FDG-PET/CT with an estimated rate of decrease in SUVmax of 0.02/day. By extrapolating a best-line fit, they estimated complete normalization of the increased metabolic activity in thrombosed veins after 84-91 days. They also found decreasing SUVmax on serial scans in two patients: One scanned on days 21, 35, and 70 had SUVmax values of 3.83, 3.03, and 1.88, respectively; another scanned on days 7, 14, and 42 had SUVmax values of 2.28, 1.99, and 1.71, respectively. SUVmax values remained remarkably consistent in the non-thrombosed veins, i.e., 1.58-1.61 and 0.90-1.02, respectively (interday coefficient of variance < 4%).
Conversely, Zhu et al. [20] evaluated the potential for early diagnosis of VTE by correlating the occurrence of FDG uptake in the lower extremities on scans performed prior to and after an established diagnosis of VTE. The results indicated a non-specific increase in FDG uptake in the lower extremities in patients with subsequent VTE compared to controls without increased FDG uptake and no history of VTE before or after the scan. The authors speculated that the increased uptake prior to VTE may represent slow inflammation that subsequently developed to fulminant VTE, but although there was a correlation, the authors advised caution. Their study was small, highly selective and retrospective and without consistent correlation between the location of FDG uptake and the site of VTE. Furthermore, the uptake lingered for a relatively long time after the event in several patients in contrast with the abovementioned results by Rondina et al. [12] . Thus, non-specific FDG uptake in the lower extremities may be a marker of patients at higher risk for subsequent diagnosis of VTE, but further and prospective studies are warranted.
VTE and cancer comorbidity
Underlying disease is a key factor in the development of VTE, the most prominent of these being cancer. VTE is a major cause of morbidity and mortality in cancer with a significant impact on both quality of life and prognosis, and VTE may be the first manifestation of malignancy. About 15% of cancer patients develop symptomatic VTE, discharged cancer patients have a twofold incidence of VTE, and cancer patients with VTE have a six-month survival rate of only 20% compared to 90% of cancer patients without VTE. One in seven in-patients are reported to die from VTE rather than their cancer, more than half presenting only with limited malignant disease and a reasonable life expectancy in the absence of VTE. Conversely, the literature reports cancer incidences of 2-12% in first time episodes of idiopathic VTE, higher in patients with recurring VTE. The risk is up to three times greater within the first 6 months after an episode of VTE, and the increased risk tends to linger for more than a decade [70, 71] . Common cancer and VTE risk factors are: hypercoagulability, immobility or impaired blood flow caused by tumors, and indwelling catheters [71] . Clinical algorithms and biochemical markers such as d-dimer to rule out DVT are not very useful in cancer patients [70] .
We have recently done a literature survey on the use of FDG-PET/CT as a screening tool for occult malignancy in unprovoked VTE (meta-analysis published as conference abstract). The systematic search yielded four studies, two prospective, one retrospective, and one randomized controlled trial comparing FDG-PET/CT for limited screening. Studies were highly heterogeneous, but the pooled FDG-PET/CT-detected cancer prevalence was 7%, all studies reported high NPV, whereas false positive rates were considerable. Generally, the results were ambiguous; i.e., one study found no significant difference between CT and FDG-PET/ CT, another reported three times higher cancer detection rate in the PET/CT group. Thus, FDG-PET/CT seems feasible as a screening tool for occult malignancy in unprovoked VTE, but the literature is sparse and highly heterogeneous, and further studies are needed to define the role of PET/CT in unprovoked VTE.
Conclusion
Out of 3897 hits, only 10 clinical studies were about FDG-PET/CT in VTE, and of these, only three were prospective while none were randomized. This illustrates an outspoken paucity of literature in a variable field. If applied early, FDG-PET/CT may have a role in the diagnosis of VTE, but not PE, for discrimination between acute and chronic VTE, and for demonstrating recurrent VTE. FDG-PET/CT is, by some, considered adept in differentiating BT from TT; however, we found this questionable because BTs may remain FDG avid for quite a while. Finally, FDG-PET/CT may be feasible when screening for occult malignancy in patients with unprovoked VTE. However, in this and in all the aforementioned areas, available literature is too sparse and too heterogeneous to draw firm conclusions about the role FDG-PET/CT in unproved VTE.
